What is it about?
The role of the neutrophil to lymphocyte ratio (NLR) and other blood cell count indexes as possible biomarkers of response to immunotherapics has been recently investigated. We discuss the encouraging results reported on the topic, provide new data from our personal experience with Nivolumab, and discuss opportunities for further research.
Featured Image
Why is it important?
The issue is important because biomarkers which allow early identification of non-responders to immunotherapy are useful in clinical practice in order to prescribe a different therapy. The indexes investigated are low cost, simple and widely available .
Perspectives
Further research is warranted to confirm the encouraging results described in the article.
Dr Panagiotis Paliogiannis
University of Sassari
Read the Original
This page is a summary of: Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab, Cancer Immunology Immunotherapy, June 2018, Springer Science + Business Media,
DOI: 10.1007/s00262-018-2182-4.
You can read the full text:
Contributors
The following have contributed to this page
